Japan PPI inflation slips to 11-mth low in July
CorMedix Inc . (NASDAQ:CRMD), a healthcare company with a market capitalization of $1.07 billion and impressive year-to-date returns of 94%, held its 2025 Annual Meeting of Stockholders on Tuesday. According to a press release statement, shareholders voted on three proposals, including the election of directors, a non-binding advisory vote on executive compensation, and the ratification of the company’s independent auditor. InvestingPro data shows the company maintains a strong financial health score, with notably high gross margins of 95%.
All seven director nominees were elected to serve until the 2026 annual meeting. Vote counts for the nominees were as follows: Janet Dillione received 15,562,263 votes for and 2,883,931 withheld; Gregory Duncan received 17,555,657 for and 890,537 withheld; Alan W. Dunton received 17,018,432 for and 1,427,762 withheld; Myron Kaplan received 14,211,986 for and 4,234,208 withheld; Steven Lefkowitz received 17,358,125 for and 1,088,069 withheld; Robert Stewart received 15,763,771 for and 2,682,423 withheld; and Joseph Todisco received 18,279,057 for and 167,137 withheld. Each nominee also had 27,599,135 broker non-votes. With earnings per share of $0.28 and positive growth expectations, InvestingPro analysis reveals 18 additional key insights about CorMedix’s performance and valuation.
Shareholders approved, on a non-binding advisory basis, the compensation paid to CorMedix’s named executive officers for 2024. The results were 16,086,287 votes for, 1,999,311 against, and 360,596 abstentions, with 27,599,135 broker non-votes.
The appointment of CBIZ (NYSE:CBZ) CPAs P.C. as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was also ratified. The vote totals were 45,476,764 for, 412,102 against, and 156,463 abstentions.
The information in this article is based on a statement from CorMedix’s SEC filing. For comprehensive analysis and detailed insights into CorMedix’s financial health, valuation metrics, and growth prospects, investors can access the full Pro Research Report available exclusively on InvestingPro.
In other recent news, CorMedix Inc. reported impressive financial results for the first quarter of 2025, with earnings per share reaching $0.32, doubling the forecasted $0.16. The company also exceeded revenue expectations, posting $39.1 million against a forecast of $32.35 million. CorMedix has revised its second-quarter net sales guidance upward to a range of $35 million to $40 million, reflecting strong business momentum. The company has expanded its agreement with a Large Dialysis Organization to implement its DefenCath product, aiming to reach 50% more patients by the second half of 2025.
RBC Capital has raised its price target on CorMedix to $17 from $13, maintaining an Outperform rating, citing continued strength in the outpatient segment and potential revenue growth. The firm anticipates significant volume growth, which could offset potential revenue erosion post-TDAPA, with opportunities in total parenteral nutrition potentially adding up to $150 million in peak revenues. CorMedix is also planning clinical studies for DefenCath in Total (EPA:TTEF) Parenteral Nutrition and Pediatric patient populations in 2025. The company remains optimistic about its mid-year implementation plans with a large dialysis operator and is targeting FDA approval for a new indication by late 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.